Mesoblast Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mesoblast Ltd with three other companies in this sector in AUSTRALIA : Cogstate Ltd (2020 sales of 35.36 million Australian Dollars [US$27.24 million] of which 89% was Clinical Trials), Idt Australia Limited. (14.17 million Australian Dollars [US$10.92 million] ), and Clinuvel Pharmaceuticals Limited (33.13 million Australian Dollars [US$25.52 million] of which 100% was Biotechnology).

Sales Analysis. Sales levels dropped significantly in the third fiscal quarter of 2021 versus the previous year's third quarter. During the third fiscal quarter of 2021, sales at Mesoblast Ltd totalled A$2.50 million. This is a drop of 86.2% from the A$18.20 million in sales at the company during the third quarter in 2020. During the first three quarters of 2021, sales totalled A$7.36 million, which is 84.3% lower than through the first three fiscal quarters of 2020. During the year ended June of 2020, sales at Mesoblast Ltd were A$47.97 million (US$36.96 million). This is an increase of 105.0% versus 2019, when the company's sales were A$23.40 million. This was the third consecutive year of growth at Mesoblast Ltd.